Autism Spectrum DisorderNCT07328438
Diagnosis Disclosure Support for Caregivers of Children With Autism
A study testing SHARE : Supporting Honest Autism Recognition and Education and One-session seminar in people with Autism Spectrum Disorder, run by Korea University.
Trial summary
The purpose of this randomized controlled pilot study is to develop and evaluate an online diagnosis disclosure support intervention for caregivers of 7- to 12-year-old children with autism spectrum disorder (ASD) in South Korea. Read more about this study
- Who is it for?
- Ages 7 to 12 years
- Conditions the study is for
- Autism Spectrum Disorder
- What is being tested?
- SHARE : Supporting Honest Autism Recognition and Education and One-session seminar
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- 5 Jan 2026to 30 Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 7 to 12 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Caregivers of children aged 7-12 (Grades 2-6) attending mainstream schools in South Korea
- Caregivers of children with previous medical diagnosis of ASD
- Caregivers with no prior experience of participation in diagnosis disclosure support programs
- Caregivers in agreement with the need for a ASD diagnosis disclosure support intervention program, with commitment to continuous and sincere participation
Who cannot join
- Caregivers of children with significant intellectual disability
- Caregivers of children with significant language delay
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Diagnosis Disclosure Support Intervention Program for Caregivers of Children With ASD
The purpose of this randomized controlled pilot study is to develop and evaluate an online diagnosis disclosure support intervention for caregivers of 7- to 12-year-old children with autism spectrum disorder (ASD) in South Korea. This intervention is designed to support caregivers who are contemplating, preparing for, or carrying out disclosure of their child's ASD diagnosis to the child. This study has three primary aims: (1) to evaluate the acceptability and feasibility of the intervention; (2) to examine clinically meaningful effects of the intervention on caregivers' psychological well-being and psychosocial adjustment (e.g., emotion regulation, loneliness/social isolation, and adaptation to life transitions), parenting competence and attitudes (e.g., parenting self-efficacy, parenting role satisfaction, and parenting stress), and autism-related knowledge and social perceptions (e.g., autism knowledge and perceived autism-related stigma); and (3) to assess whether the effects of the intervention are maintained one month after program completion.
Read the detailed description
As school-aged children with autism spectrum disorder begin to recognize differences between themselves and their neurotypical peers, they develop questions regarding their identity and belonging. During this critical developmental period, receiving a clear and supportive explanation of their diagnosis can promote self-understanding, encourage self-advocacy, and enhance psychosocial adjustment. However, caregivers often face significant barriers to disclosing the diagnosis, stemming from fear of stigma, uncertainty about appropriate timing and language, and concerns about causing emotional distress. As a result, caregivers may delay or avoid disclosure, despite potential benefits for the child. Therefore, developing evidence-based interventions to support caregivers in diagnosis disclosure is significant, yet few studies offer guidance for caregivers, leaving disclosure decisions and processes largely to individual families.
The purpose of this randomized controlled pilot study is to develop and evaluate an online diagnosis disclosure support intervention for caregivers of 7- to 12-year-old children with ASD in South Korea, a developmental period when children go through increasing cognitive, social, and identity-related challenges. This study pursues three objectives: (1) to evaluate the acceptability and feasibility of the diagnosis disclosure support intervention; (2) to examine clinically meaningful effects on caregiver's outcomes across domains such as psychological well-being and psychosocial adjustment, parenting competence and attitudes, and autism-related knowledge and social perceptions; and (3) to assess the sustainability of these effects through a one-month follow-up after program completion.
40 caregivers of children with ASD enrolled in mainstream schools (grades 2-6) in South Korea will be recruited and randomly assigned to either an intervention group (n=20) or a waitlist control group (n=20). The intervention group will participate in a five-week, online group-based diagnosis disclosure support program consisting of weekly 60-minute sessions, which will be recorded for fidelity monitoring. The waitlist control group will receive an abbreviated one-session online seminar and program materials upon completion of the final follow-up assessment. Both groups will complete online self-report measures at three timepoints: baseline (T1), immediately following the intervention group's program completion (T2), and at a one-month follow-up (T3). This study holds the potential to improve caregivers' well-being and support healthy family communication by providing evidence-based guidance to facilitate developmentally appropriate disclosure for children with ASD in South Korea.
- Conditions
- Autism Spectrum Disorder
- Being tested
- SHARE : Supporting Honest Autism Recognition and Education, One-session seminar
- Medical subject headings
- Autism Spectrum Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SHARE : Supporting Honest Autism Recognition and EducationBehavioural
Our intervention will consist of a five-week, telehealth-based group intervention (60 minutes per week) to support caregivers of children with ASD (7- to 12-year-olds) regarding diagnosis disclosure. This program provides guidance on the rationale for disclosure, strategies for initiating conversations, and the understanding that disclosure is a gradual, lifelong journey. In addition, the program helps caregivers customize disclosure based on their child's development and emotional readiness. The curriculum moves beyond didactic instruction by combining psychoeducation with experiential, participant-centered activities to support practice and application.
One-session seminarBehavioural
The control group will receive a 60-minute telehealth seminar providing a condensed overview of the SHARE program and the complete set of SHARE program materials.
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group | Experimental | Caregivers will participate in an online diagnosis disclosure support intervention delivered via telehealth over five weekly 60-minute group sessions. This program is designed to support caregivers' decision-making and communication regarding disclosure of an ASD diagnosis to their child, including key considerations for disclosure and the development of an individualized narrative to explain the diagnosis. Sessions will include psychoeducation and interactive activities to promote engagement and skill practice. Receives: Behavioral: SHARE : Supporting Honest Autism Recognition and Education |
| Waitlist Control Group | Active comparator | A one-session, group-based psychoeducational seminar delivered via telehealth will be provided to the control group. This abbreviated session will provide a condensed overview of the SHARE program, and caregivers will receive the complete SHARE program materials. Receives: Behavioral: One-session seminar |
What is being measured
The primary outcome is the main question the study is designed to answer.
Parental Autism Disclosure Scale (PADS)
The Parental Autism Disclosure Scale (PADS) is a self-report instrument developed in this study to measure the extent to which caregivers of autistic children have considered and prepared for disclosing the diagnosis to their child. The scale consists of 26 items rated on a 5-point Likert scale ranging from "strongly disagree" (0) to "strongly agree" (4), with reverse-scored items included. Higher total scores indicate greater consideration of and preparedness for disclosing the diagnosis to the child, with total scores ranging from 0 to 104.
Measured: baseline, immediately after the intervention, 1-month follow-up
Decisional Conflict Scale (DCS)
The Decisional Conflict Scale (DCS) will be used to assess decision-making conflict regarding diagnosis disclosure among caregivers of children with autism. Items are rated on a 5-point Likert scale ranging from "strongly agree" (0) to "strongly disagree" (4). Total scores and subscale scores are converted to a 0-100 scale, with higher scores indicating greater decisional conflict.
Measured: baseline, immediately after the intervention, 1-month follow-up
Diagnosis Disclosure Support Intervention Program Acceptability Survey
This will be used to assess whether the intervention program was satisfying and comprehensible to caregivers. Caregivers will respond to approximately 10 items using a Likert-type scale. The survey will include items such as "The program fits the goals of the intervention" and "The skills taught in the program are relevant to my needs."
Measured: immediately after the intervention
Diagnosis Disclosure Support Intervention Program Feasibility Survey
This will be used to assess whether the intervention program was feasible for the caregivers. Caregivers will respond to approximately 10 items using a Likert-type scale. The survey will include items related to the practicality of the program such as 'Using Zoom for the sessions was easy for me.' and 'The length of each session was manageable.'
Measured: immediately after the intervention
Participation Survey
A form will be used to record the attendance of the caregivers as a measure of their participation in the intervention program.
Measured: during each of the five sessions (weeks 1 to 5) in intervention program
Intervention Fidelity Checklist
This will be used to assess whether core elements in each session were delivered to caregivers. Interventionists will record the checklist for each session.
Measured: every 3 months from the start of the intervention for each therapist
Secondary outcomes (9)
Korean Version of Internalized Stigma of Mental Illness Scale (K-ISMI)
The Korean Version of the Internalized Stigma of Mental Illness Scale (K-ISMI) will be used to measure the level of internalized stigma experienced by caregivers and to assess the impact of stigma on family stress and adaptation. Items are rated on a 4-point Likert scale ranging from "strongly disagree" (1) to "strongly agree" (4), with reverse-scored items included. Total scores range from 29 to 116, with higher scores indicating a higher level of internalized stigma related to having a child with autism.
Measured: baseline, immediately after the intervention, 1-month follow-up
Life Transition Scale for Parents of Children with Autism (LTS)
The Life Transition Scale for Parents of Children with Autism (LTS) will be used to assess the emotional responses and psychological adaptation of caregivers of autistic children during the process of recognizing and accepting their child's diagnosis. Items are rated on a 4-point Likert scale ranging from "never" (1) to "often" (4), with reverse-scored items included. Evaluation of the transition process is conducted by calculating the mean score for each stage, obtained by dividing the sum of item scores within each stage by the number of items; higher or lower mean scores are then compared across stages.
Measured: baseline, immediately after the intervention, 1-month follow-up
Emotion Regulation Questionnaire (ERQ)
The Emotion Regulation Questionnaire (ERQ) will be used to assess how caregivers experience and regulate their emotions in their daily lives. Items are rated on a 7-point Likert scale ranging from "strongly disagree" (1) to "strongly agree" (7). Higher scores indicate greater use of the corresponding emotion regulation strategy.
Measured: baseline, immediately after the intervention, 1-month follow-up
Autism Stigma and Knowledge Questionnaire (ASK-Q-2)
The Autism Stigma and Knowledge Questionnaire (ASK-Q-2) will be used to assess caregivers' knowledge of and stigma toward autism. Items are scored dichotomously (agree = 1, disagree = 0).
Measured: baseline, immediately after the intervention, 1-month follow-up
Parenting Sense of Competence (PSOC)
The Parenting Sense of Competence (PSOC) scale is a parent self-report measure used to assess parenting satisfaction and efficacy. Items are rated on a 6-point Likert scale ranging from "strongly disagree" (1) to "strongly agree" (6), with reverse-scored items included. Higher total scores indicate greater parental efficacy. Scores of 58 or below are interpreted as low, scores between 58 and 74 as average, and scores of 75 or above as high.
Measured: baseline, immediately after the intervention, 1-month follow-up
Parent Satisfaction Scale (PSS)
The Parent Satisfaction Scale (PSS) is an instrument that assesses caregivers' subjective evaluation of their performance in the parenting role, as well as the positive and negative emotions arising from their parenting experiences. Items are rated on a 4-point Likert scale ranging from "strongly disagree" (1) to "strongly agree" (4), with reverse-scored items included. Higher total scores indicate greater satisfaction with the parenting role.
Measured: baseline, immediately after the intervention, 1-month follow-up
Korean Parenting Stress Index Fourth Edition Short Form (K-PSI-4-SF)
The Korean Parenting Stress Index-Fourth Edition Short Form (K-PSI-4-SF) is a parent self-report measure used to assess parenting stressors and overall levels of parenting stress. Items are rated on a 5-point Likert scale with varying anchor statements (e.g., from "strongly disagree" (1) to "strongly agree" (5); from "definitely not adequate as a parent" (1) to "a very good parent" (5); and from "much easier than expected" (1) to "much more difficult than expected" (5)). Total scores range from 36 to 180, with higher total scores indicating greater levels of stress experienced in parenting.
Measured: baseline, immediately after the intervention, 1-month follow-up
UCLA Loneliness Scale-8 (ULS-8)
The UCLA Loneliness Scale-8 (ULS-8) is a self-report measure that assesses the degree and frequency of perceived loneliness and will be used to measure loneliness as a state of extreme distress resulting from relational deficiency. Items are rated on a 4-point Likert scale ranging from "strongly disagree" (1) to "always" (4), with reverse-scored items included. Total scores range from 8 to 32, with higher total scores indicating higher levels of perceived loneliness.
Measured: baseline, immediately after the intervention, 1-month follow-up
Loneliness and Social Isolation Scale (LSIS)
The Loneliness and Social Isolation Scale (LSIS) is an instrument designed to estimate the complex construct of social isolation by incorporating both objectively measurable aspects of social networks and individuals' subjective perceptions of social support and loneliness. Items 1 and 2 are rated on a scale ranging from "rarely true" (0) to "very true" (3). Items 3 and 4 are reverse-scored, ranging from "rarely true" (3) to "very true" (0). Item 5 assesses the number of social contacts, scored from "0 persons" (3) to "7 or more persons" (0), and Item 6 assesses time spent in social interaction, scored from "not at all" (3) to "1 hour or more" (0). A total score of 3 or higher on Items 1 and 2 indicates a high risk of loneliness. A total score of 4 or higher on Items 3 and 4, together with a total score of 4 or higher on Items 5 and 6, indicates a high risk of social isolation.
Measured: baseline, immediately after the intervention, 1-month follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jan 2026
- Study start5 Jan 2026 (estimated)
- Primary completion30 Apr 2026 (estimated)
- Study completion30 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Autism Spectrum DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized Waitlist Control Group Design
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Korea University
- Sponsor type
- University, hospital or other
- Collaborators
- National Research Foundation of Korea
- Responsible party
- Principal investigator, So Hyun Kim, Korea University
- Investigators
- So Hyun Kim, Ph.D., Principal investigator, Korea UniversityKyoung Hong, Ph.D., Study director, Korea University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07328438
- Sponsor's protocol ID
- IRB-2025-0578-01
- Other IDs
- 00209635
- Status last verified
- Jan 2026
- First submitted
- 19 Dec 2025
- Last updated
- 21 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diagnosis Disclosure Support Intervention Program for Caregivers of Children With ASD
- ClinicalTrials.gov ID
- NCT07328438
- Acronym / sponsor ID
- IRB-2025-0578-01
- Conditions
- Autism Spectrum Disorder
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Korea UniversityUniversity, hospital or other
- Collaborators
- National Research Foundation of Korea
- Study start
- 5 Jan 2026 (estimated)
- Primary completion
- 30 Apr 2026 (estimated)
- Study completion
- 30 Apr 2027 (estimated)
- First posted
- 9 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this randomized controlled pilot study is to develop and evaluate an online diagnosis disclosure support intervention for caregivers of 7- to 12-year-old children with autism spectrum disorder (ASD) in South Korea. This intervention is designed to support caregivers who are contemplating, preparing for, or carrying out disclosure of their child's ASD diagnosis to the child. This study has three primary aims: (1) to evaluate the acceptability and feasibility of the intervention; (2) to examine clinically meaningful effects of the intervention on caregivers' psychological well-being and psychosocial adjustment (e.g., emotion regulation, loneliness/social isolation, and adaptation to life transitions), parenting competence and attitudes (e.g., parenting self-efficacy, parenting role satisfaction, and parenting stress), and autism-related knowledge and social perceptions (e.g., autism knowledge and perceived autism-related stigma); and (3) to assess whether the effects of the intervention are maintained one month after program completion.
Detailed description
As school-aged children with autism spectrum disorder begin to recognize differences between themselves and their neurotypical peers, they develop questions regarding their identity and belonging. During this critical developmental period, receiving a clear and supportive explanation of their diagnosis can promote self-understanding, encourage self-advocacy, and enhance psychosocial adjustment. However, caregivers often face significant barriers to disclosing the diagnosis, stemming from fear of stigma, uncertainty about appropriate timing and language, and concerns about causing emotional distress. As a result, caregivers may delay or avoid disclosure, despite potential benefits for the child. Therefore, developing evidence-based interventions to support caregivers in diagnosis disclosure is significant, yet few studies offer guidance for caregivers, leaving disclosure decisions and processes largely to individual families.
The purpose of this randomized controlled pilot study is to develop and evaluate an online diagnosis disclosure support intervention for caregivers of 7- to 12-year-old children with ASD in South Korea, a developmental period when children go through increasing cognitive, social, and identity-related challenges. This study pursues three objectives: (1) to evaluate the acceptability and feasibility of the diagnosis disclosure support intervention; (2) to examine clinically meaningful effects on caregiver's outcomes across domains such as psychological well-being and psychosocial adjustment, parenting competence and attitudes, and autism-related knowledge and social perceptions; and (3) to assess the sustainability of these effects through a one-month follow-up after program completion.
40 caregivers of children with ASD enrolled in mainstream schools (grades 2-6) in South Korea will be recruited and randomly assigned to either an intervention group (n=20) or a waitlist control group (n=20). The intervention group will participate in a five-week, online group-based diagnosis disclosure support program consisting of weekly 60-minute sessions, which will be recorded for fidelity monitoring. The waitlist control group will receive an abbreviated one-session online seminar and program materials upon completion of the final follow-up assessment. Both groups will complete online self-report measures at three timepoints: baseline (T1), immediately following the intervention group's program completion (T2), and at a one-month follow-up (T3). This study holds the potential to improve caregivers' well-being and support healthy family communication by providing evidence-based guidance to facilitate developmentally appropriate disclosure for children with ASD in South Korea.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Randomized Waitlist Control Group Design
| Arm | Type | Receives |
|---|---|---|
| Intervention Group | Experimental | Behavioral: SHARE : Supporting Honest Autism Recognition and EducationCaregivers will participate in an online diagnosis disclosure support intervention delivered via telehealth over five weekly 60-minute group sessions. This program is designed to support caregivers' decision-making and communication regarding disclosure of an ASD diagnosis to their child, including key considerations for disclosure and the development of an individualized narrative to explain the diagnosis. Sessions will include psychoeducation and interactive activities to promote engagement and skill practice. |
| Waitlist Control Group | Active comparator | Behavioral: One-session seminarA one-session, group-based psychoeducational seminar delivered via telehealth will be provided to the control group. This abbreviated session will provide a condensed overview of the SHARE program, and caregivers will receive the complete SHARE program materials. |
Who may qualify
- Ages
- 7 to 12 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- Caregivers of children aged 7-12 (Grades 2-6) attending mainstream schools in South Korea
- Caregivers of children with previous medical diagnosis of ASD
- Caregivers with no prior experience of participation in diagnosis disclosure support programs
- Caregivers in agreement with the need for a ASD diagnosis disclosure support intervention program, with commitment to continuous and sincere participation
Key exclusion criteria (2 listed)
- Caregivers of children with significant intellectual disability
- Caregivers of children with significant language delay
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SHARE : Supporting Honest Autism Recognition and EducationOur intervention will consist of a five-week, telehealth-based group intervention (60 minutes per week) to support caregivers of children with ASD (7- to 12-year-olds) regarding diagnosis disclosure. This program provides guidance on the rationale for disclosure, strategies for initiating conversations, and the understanding that disclosure is a gradual, lifelong journey. In addition, the program helps caregivers customize disclosure based on their child's development and emotional readiness. The curriculum moves beyond didactic instruction by combining psychoeducation with experiential, participant-centered activities to support practice and application. | Behavioural | Intervention Group |
| One-session seminarThe control group will receive a 60-minute telehealth seminar providing a condensed overview of the SHARE program and the complete set of SHARE program materials. | Behavioural | Waitlist Control Group |
Primary outcome
Parental Autism Disclosure Scale (PADS)
Time frame: baseline, immediately after the intervention, 1-month follow-up
The Parental Autism Disclosure Scale (PADS) is a self-report instrument developed in this study to measure the extent to which caregivers of autistic children have considered and prepared for disclosing the diagnosis to their child. The scale consists of 26 items rated on a 5-point Likert scale ranging from "strongly disagree" (0) to "strongly agree" (4), with reverse-scored items included. Higher total scores indicate greater consideration of and preparedness for disclosing the diagnosis to the child, with total scores ranging from 0 to 104.
Decisional Conflict Scale (DCS)
Time frame: baseline, immediately after the intervention, 1-month follow-up
The Decisional Conflict Scale (DCS) will be used to assess decision-making conflict regarding diagnosis disclosure among caregivers of children with autism. Items are rated on a 5-point Likert scale ranging from "strongly agree" (0) to "strongly disagree" (4). Total scores and subscale scores are converted to a 0-100 scale, with higher scores indicating greater decisional conflict.
Diagnosis Disclosure Support Intervention Program Acceptability Survey
Time frame: immediately after the intervention
This will be used to assess whether the intervention program was satisfying and comprehensible to caregivers. Caregivers will respond to approximately 10 items using a Likert-type scale. The survey will include items such as "The program fits the goals of the intervention" and "The skills taught in the program are relevant to my needs."
Diagnosis Disclosure Support Intervention Program Feasibility Survey
Time frame: immediately after the intervention
This will be used to assess whether the intervention program was feasible for the caregivers. Caregivers will respond to approximately 10 items using a Likert-type scale. The survey will include items related to the practicality of the program such as 'Using Zoom for the sessions was easy for me.' and 'The length of each session was manageable.'
Participation Survey
Time frame: during each of the five sessions (weeks 1 to 5) in intervention program
A form will be used to record the attendance of the caregivers as a measure of their participation in the intervention program.
Intervention Fidelity Checklist
Time frame: every 3 months from the start of the intervention for each therapist
This will be used to assess whether core elements in each session were delivered to caregivers. Interventionists will record the checklist for each session.
9 secondary outcomes
Korean Version of Internalized Stigma of Mental Illness Scale (K-ISMI)
Time frame: baseline, immediately after the intervention, 1-month follow-up
Life Transition Scale for Parents of Children with Autism (LTS)
Time frame: baseline, immediately after the intervention, 1-month follow-up
Emotion Regulation Questionnaire (ERQ)
Time frame: baseline, immediately after the intervention, 1-month follow-up
Autism Stigma and Knowledge Questionnaire (ASK-Q-2)
Time frame: baseline, immediately after the intervention, 1-month follow-up
Parenting Sense of Competence (PSOC)
Time frame: baseline, immediately after the intervention, 1-month follow-up
Parent Satisfaction Scale (PSS)
Time frame: baseline, immediately after the intervention, 1-month follow-up
Korean Parenting Stress Index Fourth Edition Short Form (K-PSI-4-SF)
Time frame: baseline, immediately after the intervention, 1-month follow-up
UCLA Loneliness Scale-8 (ULS-8)
Time frame: baseline, immediately after the intervention, 1-month follow-up
Loneliness and Social Isolation Scale (LSIS)
Time frame: baseline, immediately after the intervention, 1-month follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jan 2026.
Related trials for Autism Spectrum Disorder
RecruitingPhase 1
Cannabidiol (CBD) in Adults With ASD
Autism Spectrum Disorder
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Sensory-integration Therapy Verses Augumented Reality-based Training in ASD
Autism Spectrum Disorder
Recruiting
Cumulative and Booster Effects of Multisession Prefrontal tDCS in ASD Adolescents
Transcranial Direct Current Stimulation, Autistic Spectrum Disorder
Not yet recruiting
"Family Resilience And Mind-body Enhancement" (FRAME): A Randomised Controlled Trial
Autism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
So Hyun Kim, Ph.D. principal investigator
Korea University
Kyoung Hong, Ph.D. study director
Korea University
Questions about this trial
What is this clinical trial studying?
A study testing SHARE : Supporting Honest Autism Recognition and Education and One-session seminar in people with Autism Spectrum Disorder, run by Korea University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact So Hyun Kim, Ph.D. (+82-2-3290-2065, sohkim@korea.ac.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Parental Autism Disclosure Scale (PADS) (time frame: baseline, immediately after the intervention, 1-month follow-up). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2026.